Design, Development, and Characterization of High Drug-Loaded Drug-Drug-Polymer Ternary Amorphous Solid Dispersions
- PMID: 40328992
- DOI: 10.1208/s12249-025-03123-6
Design, Development, and Characterization of High Drug-Loaded Drug-Drug-Polymer Ternary Amorphous Solid Dispersions
Abstract
Ternary amorphous solid dispersions (TASD) are a three-component system that incorporates at least one drug in an amorphous form, offering potential advantages over conventional binary amorphous solid dispersions (ASD). This study aimed to design, characterize, and evaluate a stable and soluble high drug-loaded TASD combining two poorly water-soluble drugs, curcumin (CUR) and resveratrol (RES), with a hydrophilic polymer. Polymer screening studies, including miscibility, crystallization tendency, Flory-Huggins interaction parameter, and solubility parameter, were complemented by advanced techniques such as crystallization kinetics and molecular interaction analysis to assess drug-polymer interactions and amorphous stability. After selecting the optimal polymer, TASDs were prepared by rotary evaporation. Pure drugs, physical mixtures, binary, and ternary ASDs were characterized using X-ray diffraction (XRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier-transform infrared (FTIR) spectroscopy, and Raman spectroscopy. In-vitro dissolution under non-sink conditions was performed using a USP-II apparatus, and centrifuged samples were analyzed by UV-Vis spectroscopy. Long-term physical stability was assessed over 12 months at room temperature. Eudragit EPO was identified as the optimal polymer among EPO, HPMCAS, and S100. The resulting high drug-loaded (50% w/w) TASD was amorphous, exhibiting a single glass transition temperature (Tg) with strong drug-polymer interactions. In dissolution studies, the 50% drug-loaded TASD showed a ~ 197-fold and ~ fourfold increase in dissolved CUR and RES, respectively, compared to the crystalline drugs in the physical mixture after 1 h in acidic condition. Despite a lower RES release, it was still twice the release from binary ASDs. The TASD formulation remained physically amorphous for 12 months at room temperature storage.
Keywords: amorphous; interaction; poorly soluble compounds; solid dispersion; stability.
© 2025. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Conflict of interest statement
Declarations. Conflict of interest: The author declares that there is no conflict of interest.
Similar articles
-
Hydrophilic and Amphiphilic Macromolecules as Modulators of the Physical Stability and Bioavailability of Piribedil: A Study on Binary Mixtures and Micellar Systems.Mol Pharm. 2025 Aug 4;22(8):4708-4730. doi: 10.1021/acs.molpharmaceut.5c00276. Epub 2025 Jun 30. Mol Pharm. 2025. PMID: 40586556 Free PMC article.
-
Harnessing dicarboxylate-based salts for enhancing the performance of amorphous solid dispersions: The case of olanzapine.Eur J Pharm Biopharm. 2025 Sep;214:114782. doi: 10.1016/j.ejpb.2025.114782. Epub 2025 Jun 11. Eur J Pharm Biopharm. 2025. PMID: 40513757
-
High drug-loaded amorphous solid dispersions of a poor glass forming drug: The impact of polymer type and cooling rate on amorphous drug behaviour.Int J Pharm. 2025 Feb 10;670:125095. doi: 10.1016/j.ijpharm.2024.125095. Epub 2024 Dec 15. Int J Pharm. 2025. PMID: 39689829
-
Navigating the Solution to Drug Formulation Problems at Research and Development Stages by Amorphous Solid Dispersion Technology.Recent Adv Drug Deliv Formul. 2024;18(2):79-99. doi: 10.2174/0126673878271641231201065151. Recent Adv Drug Deliv Formul. 2024. PMID: 38062659 Review.
-
Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.Drug Dev Ind Pharm. 2015;41(9):1401-15. doi: 10.3109/03639045.2015.1018274. Epub 2015 May 20. Drug Dev Ind Pharm. 2015. PMID: 25853292 Review.
References
-
- Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery – An update. Int J Pharm. 2018 15;535(1):379–92.
-
- Borde S, Paul SK, Chauhan H. Ternary solid dispersions: Classification and formulation considerations. Drug Dev Ind Pharm. 2021;0(ja):1–73.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous